AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 30
Study 23151693 — intervention group
Group type: COMPARATOR
Intervention: Colgate Plax
Number of subjects: 30
Study 19678778 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical six‐point acupuncture
Number of subjects: 68
Study 19678778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondefined-point acupuncture
Number of subjects: 68
Study 17472017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (12.5 mg hydrochlorothiazide + 5 mg felodipine)
Number of subjects: 9711
Study 17472017 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (12.5 mg hydrochlorothiazide + placebo)
Number of subjects: 9711
Study 15703092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (10 ml periprostatic)
Number of subjects: 40
Study 15703092 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (10 ml periprostatic)
Number of subjects: 40
Study 15362028 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 142
Study 15362028 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine (3 g/day)
Number of subjects: 142
Study 11878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 177
Study 11878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 177
Study 11878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus Ondansetron 4 mg
Number of subjects: 177
Study 9861111 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 s duration of compression of the common carotid artery
Number of subjects: 23
Study 9861111 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 s duration of compression of the common carotid artery
Number of subjects: 23
Study 9861111 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 s duration of compression of the common carotid artery
Number of subjects: 23
Study 9861111 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 s duration of compression of the common carotid artery
Number of subjects: 23
Study 9861111 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ratio of 40% or more
Number of subjects: 23
Study 8198930 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg day-1
Number of subjects: 25
Study 8198930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg day-1
Number of subjects: 25
Study 8198930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2836565 — intervention group
Group type: EXPERIMENTAL
Intervention: CP at 120 mg/m2 over one hour on day 1, plus fluorouracil (5‐FU) at 1,000 mg/m2 over 24 hours as a continuous infusion on days 1 through 5
Number of subjects: 60
Study 2836565 — intervention group
Group type: COMPARATOR
Intervention: CP/5‐FU as in A, plus DDTC at 600 mg/m2 over 30 minutes administered IV exactly 30 minutes after CP infusion, plus DDTC at 200 mg/m2 administered IV over 30 minutes on days 8 and 15
Number of subjects: 60
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (pantoprazole capsules, 40 mg)
Number of subjects: 175
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (pantoprazole tablets, 40 mg)
Number of subjects: 175
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (lansoprazole, 30 mg)
Number of subjects: 175
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (esomeprazole, 20 mg)
Number of subjects: 175
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (rabeprazole, 10 mg)
Number of subjects: 175
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Total eradication rates
Number of subjects: 175
Study 29876770 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal symptoms and stool type
Number of subjects: 175
Study 28981763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy and postnatal home visits by Village Health Teams (VHTs)
Number of subjects: 1584
Study 28981763 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visit programme staffed by volunteer VHTs
Number of subjects: 1584
Study 28981763 — intervention group
Group type: EXPERIMENTAL
Intervention: VHTs spending an average of 6 hours a week on the programme
Number of subjects: 1584
Study 26699168 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (maximum dose, 1600 μg twice daily)
Number of subjects: 1156
Study 26699168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study 26699168 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156
Study 20814970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neridronate (100 mg infusion for 2 consecutive days)
Number of subjects: 56
Study 20814970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate (25 mg injection weekly for 2 months)
Number of subjects: 56
Study 20814970 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 56
Study 18053632 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 19
Study 18053632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16469206 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based general anaesthesia
Number of subjects: 70
Study 16469206 — intervention group
Group type: COMPARATOR
Intervention: Thiopental-sevoflurane-based anaesthesia
Number of subjects: 70
Study 12830671 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-informed group (unaware of the storing capacity of the device)
Number of subjects: 48
Study 12830671 — intervention group
Group type: COMPARATOR
Intervention: Informed group (aware of the storing capacity of the device)
Number of subjects: 48
Study 12830671 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-informed group
Number of subjects: 48
Study 11023759 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 2% cream
Number of subjects: 60
Study 11023759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8828528 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment of asthma based on the International Consensus Report on the Management of Asthma
Number of subjects: 0
Study 1405323 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (15, 50, or 150 U/kg) given intravenously every other day for four injections
Number of subjects: 46
Study 3902377 — intervention group
Group type: EXPERIMENTAL
Intervention: New suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Number of subjects: 10
Study 3902377 — intervention group
Group type: COMPARATOR
Intervention: Old suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Number of subjects: 10
Study 3902377 — intervention group
Group type: EXPERIMENTAL
Intervention: New suppositories
Number of subjects: 10
Study 3902377 — intervention group
Group type: COMPARATOR
Intervention: Old suppositories
Number of subjects: 10
Study 31329819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Distraction
Number of subjects: 33
Study 31329819 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Distraction
Number of subjects: 33
Study 31329819 — intervention group
Group type: COMPARATOR
Intervention: Standard Administration
Number of subjects: 33
Study 27766347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemia intervention
Number of subjects: 1328
Study 27766347 — intervention group
Group type: COMPARATOR
Intervention: Standard management of hyperglycaemia
Number of subjects: 1328
Study 27766347 — intervention group
Group type: COMPARATOR
Intervention: BP intervention
Number of subjects: 1328
Study 27766347 — intervention group
Group type: COMPARATOR
Intervention: Lipid intervention
Number of subjects: 1328
Study 27919285 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (EN-PENS)
Number of subjects: 76
Study 27919285 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (sham)
Number of subjects: 76
Study 23740399 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with sodium bicarbonate as an adjunct to 2% lignocaine and 1:80,000 adrenaline
Number of subjects: 200
Study 23740399 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration with 2% lignocaine and 1:80,000 adrenaline
Number of subjects: 200
Study 22392172 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-integrated behavioral intervention
Number of subjects: 390
Study 19027313 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 199
Study 19027313 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 199
Study 17418038 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (PG) treatment group
Number of subjects: 56
Study 17418038 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 17418038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 15229622 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + ACEI (Group A)
Number of subjects: 1600
Study 15229622 — intervention group
Group type: COMPARATOR
Intervention: Statin only (Group B)
Number of subjects: 1600
Study 15229622 — intervention group
Group type: COMPARATOR
Intervention: ACEI only (Group C)
Number of subjects: 1600
Study 15229622 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group D)
Number of subjects: 1600
Study 11980769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.25 mg/day combined with continuous E(2) 2 mg/day
Number of subjects: 134
Study 11980769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.5 mg/day
Number of subjects: 134
Study 11980769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.05 mg and 0.1 mg
Number of subjects: 134
Study 10431997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (0.27 mmol/kg)
Number of subjects: 38
Study 10431997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7587856 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial regular insulin combined with glibenclamide (group D)
Number of subjects: 80
Study 7587856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin combined with glibenclamide (group N)
Number of subjects: 80
Study 7587856 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 80
Study 2119355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 38
Study 2119355 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 38
Study 2119355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin and Amitriptyline
Number of subjects: 38
Study 6153603 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐contingent stimulation
Number of subjects: 24
Study 6153603 — intervention group
Group type: COMPARATOR
Intervention: random (non‐contingent) stimulation
Number of subjects: 24
Study 6499724 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking one cigarette
Number of subjects: 18
Study 6499724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smoking)
Number of subjects: 18
Study 29949174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride combined with etomidate fat emulsion (Group C)
Number of subjects: 90
Study 29949174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride (Group A)
Number of subjects: 90
Study 29949174 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate fat emulsion (Group B)
Number of subjects: 90
Study 29949174 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A and B)
Number of subjects: 90
Study 27609856 — intervention group
Group type: EXPERIMENTAL
Intervention: In-centre nocturnal haemodialysis (INHD)
Number of subjects: 0
Study 27609856 — intervention group
Group type: COMPARATOR
Intervention: Conventional daytime dialysis
Number of subjects: 0
Study 24714349 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) approach
Number of subjects: 160
Study 24714349 — intervention group
Group type: COMPARATOR
Intervention: Median sternotomy (MS) approach
Number of subjects: 160
Study 22976655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase treatment (Twin Block therapy followed by fixed appliance therapy with nonextraction)
Number of subjects: 146
Study 22976655 — intervention group
Group type: COMPARATOR
Intervention: 1-phase treatment (fixed appliance therapy with extraction of 4 first premolars)
Number of subjects: 146
Study 22976655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase treatment
Number of subjects: 146
Study 22976655 — intervention group
Group type: COMPARATOR
Intervention: 1-phase treatment
Number of subjects: 146
Study 20210799 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 1140
Study 20210799 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Radiation Therapy (WBRT)
Number of subjects: 1140
Study 18321879 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalon herpes simplex virus type 2 ELISA (index value of 1.5)
Number of subjects: 820
Study 15202583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 15202583 — intervention group
Group type: COMPARATOR
Intervention: Selective estrogen receptor modifiers
Number of subjects: 0
Study 12041926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (7 patients with acute gastrointestinal perforation)
Number of subjects: 22
Study 12041926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (5 critically ill patients)
Number of subjects: 22
Study 12041926 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 controls)
Number of subjects: 22
Study 12041926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and B
Number of subjects: 22
Study 9394687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (providing approximately 1672 kJ (400 kcal) energy/d)
Number of subjects: 231
Study 9394687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (for those who received it before age 18 months, n = 73)
Number of subjects: 231
Study 9394687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 231
Study 7944506 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of oral vitamin E (alpha-tocopherol acetate)
Number of subjects: 0
Study 7944506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3225767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg immediate release (IR) tablet given twice daily
Number of subjects: 24
Study 3225767 — intervention group
Group type: COMPARATOR
Intervention: 5-mg sustained-release (SR) capsule formulations given daily
Number of subjects: 24
Study 29673631 — intervention group
Group type: EXPERIMENTAL
Intervention: iHPC (prechopping method using a Reverse Chopper)
Number of subjects: 32
Study 26621854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 210
Study 26621854 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 210
Study 26621854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24981319 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks (induction dosing: 400 mg at Weeks 0, 2, and 4)
Number of subjects: 230
Study 24981319 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) with non-MTX DMARDs
Number of subjects: 230
Study 24981319 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) monotherapy
Number of subjects: 230
Study 24981319 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 230
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: RC‐5000 (Tomey Corp., Japan)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: KR‐8000 (Topcon, Japan)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster (Carl Zeiss Meditec, Germany)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: E300 (Medmont International, Australia)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: Allegro Topolyzer (Wavelight AG, Germany)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vista (EyeSys, TX)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam (Oculus, Germany)
Number of subjects: 35
Study 23049823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirius (CSO, Italy)
Number of subjects: 35
Study 23049823 — intervention group
Group type: COMPARATOR
Intervention: EyeSys Vista and Medmont E300
Number of subjects: 35
Study 20974604 — intervention group
Group type: EXPERIMENTAL
Intervention: GW274150 60 mg
Number of subjects: 366
Study 20974604 — intervention group
Group type: EXPERIMENTAL
Intervention: GW274150 120 mg
Number of subjects: 366
Study 20974604 — intervention group
Group type: EXPERIMENTAL
Intervention: GW274150 60 mg (Part 2)
Number of subjects: 366
Study 20974604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Part 1)
Number of subjects: 366
Study 20974604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Part 2)
Number of subjects: 366
Study 17697915 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 16141420 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (2 to 4 mg perindopril plus 2.0 to 2.5 mg indapamide for those without contraindications)
Number of subjects: 476
Study 11952446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular 20 mL 0.5% bupivacaine with epinephrine (B + E‐group)
Number of subjects: 120
Study 11952446 — intervention group
Group type: COMPARATOR
Intervention: Saline with epinephrine (S + E‐group)
Number of subjects: 120
Study 9772936 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg sustained release
Number of subjects: 690
Study 7531877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 30
Study 7531877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2535914 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccomanno technique
Number of subjects: 103
Study 2535914 — intervention group
Group type: COMPARATOR
Intervention: Fresh smears
Number of subjects: 103
Study 162676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 50
Study 162676 — intervention group
Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 50
Study 31788825 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation based on a cognitive-behavioral approach (5 sessions over 4 weeks)
Number of subjects: 90
Study 31788825 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation based on a cognitive-behavioral approach
Number of subjects: 90
Study 31783672 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention program (iNIP)
Number of subjects: 82
Study 31783672 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 82
Study 28658026 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL/min
Number of subjects: 100
Study 28658026 — intervention group
Group type: COMPARATOR
Intervention: 250 mL/min
Number of subjects: 100
Study 27063854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg plus Solifenacin 5 mg
Number of subjects: 2174
Study 27063854 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 2174
Study 27063854 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 2174
Study 25189764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) with blood glucose target between 4.4 and 6 mmol.L(‐1)
Number of subjects: 188
Study 25189764 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose management with blood glucose target between 5.5 and 9 mmol.L(‐1)
Number of subjects: 188
Study 25189764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 188
Study 25189764 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose management
Number of subjects: 188
Study 25189764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study 22930999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait expectancies
Number of subjects: 0
Study 22930999 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype expectancies
Number of subjects: 0
Study 22930999 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19288080 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) in femoral tunnels at the end of surgery (Group B)
Number of subjects: 40
Study 19288080 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) in femoral tunnels at the end of surgery and intra-articular at 2- and 4 weeks after surgery (Group C)
Number of subjects: 40
Study 19288080 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) activated with thrombin in the femoral tunnels (Group D)
Number of subjects: 40
Study 19288080 — intervention group
Group type: COMPARATOR
Intervention: No platelet-rich plasma (Group A)
Number of subjects: 40
Study 17594856 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned tuna in olive oil with isoflavones
Number of subjects: 400
Study 17594856 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned tuna in olive oil with omega-3 fatty acids
Number of subjects: 400
Study 17594856 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned tuna in olive oil with phytosterols
Number of subjects: 400
Study 17594856 — intervention group
Group type: COMPARATOR
Intervention: Canned tuna in olive oil alone (control group)
Number of subjects: 400
Study 15099664 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (32/8 mg)
Number of subjects: 8
Study 15099664 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (16/4 mg)
Number of subjects: 8
Study 15099664 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (8/2 mg)
Number of subjects: 8